Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Placebo-Controlled, Double-Blind, 2-Period Crossover Study to Assess Cardiac and General Safety and Pharmacokinetics of a Single Subcutaneous Dose of 60 mg MGN1703 in Healthy Volunteers

NCT01982747 is registered in ClinicalTrials.gov with Mologen AG as lead sponsor.

NCT NCT01982747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01982747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Placebo-Controlled, Double-Blind, 2-Period Crossover Study to Assess Cardiac and General Safety and Pharmacokinetics of a Single Subcutaneous Dose of 60 mg MGN1703 in Healthy Volunteers
Lead sponsor
Mologen AG
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2013
Completion date
December 31, 2013
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy